Sorrento Therapeutics, Inc. has entered a definitive agreement to acquire San Diego-based Concortis Biosystems, Corp., providing Sorrento with a comprehensive technology platform for generation of antibody drug conjugates (ADC). Upon closing, Sorrento will issue an aggregate of 1,331,978 shares of its common stock to Concortis shareholders. This acquisition will enable Sorrento to use the antibodies identified from its G-MAB library along with Concortis’ conjugation technologies and novel...